Each year diabetes researchers from all over the world gather for the annual meeting of the Advanced Technologies & Treatments for Diabetes (ATTD), which will take place on February 20-23 in Berlin. Many of the latest advances will be discussed, and includes research that Breakthrough T1D has funded to advance new breakthroughs and therapies for people with type 1 diabetes (T1D). In total, 23 researchers presenting are Breakthrough T1D-funded, either now or in the past, and four members of the Breakthrough T1D team are either presenting or moderating.
Here are highlights of Breakthrough T1D-funded research that will be featured at the ATTD Conference:
- Time in Range: Time in range as an outcome in clinical trials (Roy Beck, M.D., Ph.D.)
- Automated Insulin Delivery (AID) Systems: The promising frontier of next-generation AID systems (Eric Renard, M.D., Ph.D.)
- Closed-Loop Systems: Where are we now? (Roman Hovorka, M.Sc., Ph.D.)
- Artificial Pancreas: A synthetic version of the pancreatic hormone amylin, called pramlintide, in the artificial pancreas system (Ahmad Haidar, Ph.D.)
- SGLT Inhibition: The concept of SGLT in T1D (Chantal Mathieu, M.D., Ph.D.); report on the consensus on SGLT inhibition in T1D (Thomas Danne, M.D.)
- Psychosocial Interventions: Preventing poor psychosocial and blood sugar outcomes in teens with T1D (Korey Hood, Ph.D.)
- Outcome-Driven Medicine: Patient-reported outcome measures, T1D apps and exercise (Michael Riddell, Ph.D.)
- Open Protocol: Interoperable and do-it-yourself systems (Aaron Kowalski, Ph.D.)
- Pregnancy: Technology and pregnancy (Helen Murphy, D., FRACP)
